Clinical Trial: Dato-DXd With or Without Durvalumab in Stage I-III TNBC
Researchers are conducting a phase 3 trial to compare Dato-DXd, with or without durvalumab, to investigator’s choice of treatment in patients with TNBC.
Researchers are conducting a phase 3 trial to compare Dato-DXd, with or without durvalumab, to investigator’s choice of treatment in patients with TNBC.
Researchers are conducting a phase 3 study to compare tarlatamab to standard care in patients with relapsed or refractory small cell lung cancer.
Researchers are comparing gedatolisib plus fulvestrant, with or without palbociclib, to standard treatment for HR+, HER2- advanced breast cancer.
Researchers are conducting a phase 3 study to compare a coformulation of pembrolizumab and vibostolimab to pembrolizumab alone as first-line treatment for PD-L1-positive, metastatic NSCLC.
Researchers are evaluating a cancer vaccine, AST-301, as adjuvant treatment for patients with HR-negative, HER2-low breast cancer.
Researchers are conducting a phase 3 study to compare zimberelimab plus domvanalimab to pembrolizumab in patients with PD-L1-high, locally advanced or metastatic NSCLC.
Researchers are evaluating pembrolizumab plus investigator’s choice of chemotherapy in HR+, HER2-, locally recurrent inoperable or metastatic breast cancer.
Researchers are comparing atezolizumab maintenance to maintenance with lurbinectedin and atezolizumab in patients with ES-SCLC.
Researchers are conducting a phase 3 trial to evaluate TOL2506, an extended-release formulation of leuprolide acetate, in patients with breast cancer.
Researchers are conducting a phase 1b/2 trial to compare various durvalumab-based combinations in patients with metastatic triple-negative breast cancer.